Isoliquiritigenin Suppresses Osteosarcoma U2OS Cell Proliferation and Invasion by Regulating the PI3K/Akt Signalling Pathway
- Chemotherapy. 2018;63(3):155-161. doi: 10.1159/000490151.
- 1. Department of Orthopaedics, the Second Hospital of Peking Armed Polce, Beijing, China.
- 2. Department of Orthopaedics, the Affiliated Hospital of Academy of Military Medical Sciences, PLA 307th Hospital, Beijing, China.
- 3. Department of General Surgery, Xinjiang Municipal Corps Hospital CAPF, Urumqi, China.
- 4. Department of Medicine, Xinjiang Municipal Corps Hospital CAPF, Urumqi, China.
- 5. Department of Cadre's Ward 2, General Hospital of Chinese People Armed Police Forces, Beijing, China.
Aims: Isoliquiritigenin (ISL) is a flavonoid, that has been shown to have antioxidant, vasorelaxant, anti-inflammatory, and antitumor activities. This study aimed to explore the antitumor effect of ISL on human osteosarcoma U2OS cells and investigate the mechanism of this effect.
Methods: The effect of ISL on osteosarcoma U2OS cell proliferation, invasion, migration, and Apoptosis were determined by a CCK8 assay, a transwell invasion assay, a transwell migration assay, and fluorescence-activated cell sorting, respectively. In addition, the protein expression levels of Bcl2, Bax, active Caspase-3, Akt, mTOR, p70, and Cyclin D1 were detected by western blotting.
Results: ISL suppressed cell proliferation, inhibited invasion and migration, and promoted Apoptosis in U2OS cells. After treatment with ISL, the protein expression levels of Bax and active Caspase-3 increased, while the level of Bcl-2 declined significantly. Furthermore, the phosphorylation levels of Akt and mTOR declined significantly compared with that of the control.
Conclusion: ISL could retard proliferation and promote Apoptosis of U2OS cells possibly by suppressing the PI3K/Akt signalling pathway, indicating that it might be a potential therapeutic agent for osteosarcoma treatment.
-
Cat. No.Product NameDescriptionTargetResearch Area
-